Daniel S. Reuland

Daniel S. Reuland

Auto-generated profile, based on publicly available information

Daniel S. Reuland

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, USA

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2010 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
DHDebra J. Holden
Debra J. Holden
DJDaniel E. Jonas
Daniel E. Jonas
DPDeborah S. Porterfield
Deborah S. Porterfield
DRDaniel Reuland
Daniel Reuland
RHRussell Harris
Russell Harris
National guideline groups recommend screening and discussion of screening options for persons at average risk for colorectal cancer (CRC). However, emerging evidence suggests that CRC screening is simultaneously underused, overused, and misused and that adequate patient-provider discussions about screening are infrequent. To summarize evidence on factors that influence CRC screening and strategies that increase the appropriate use and quality of CRC screening and CRC screening discussions. MEDLINE, the Cochrane Library, and the Cochrane Central Register of Controlled Trials were searched for English-language publications describing studies conducted in the United States from January 1998 through September 2009. Two reviewers independently selected studies that addressed the study questions and met eligibility criteria. Information on study design, setting, intervention, outcomes, and quality were extracted by one reviewer and double-checked by another. Reviewers assigned a strength-of-evidence grade for intervention categories by using criteria plus a consensus process. Reviewers found evidence of simultaneous underuse, overuse, and misuse of CRC screening as well as inadequate clinical discussions about CRC screening. Several patient-level factors were independently associated with lower screening rates, including having low income or less education, being uninsured, being Hispanic or Asian, being less acculturated into the United States, or having limited access to care. Evidence that interventions that included patient reminders or one-on-one interactions (that is, between patients and nonphysician clinic staff), eliminated structural barriers (for example, simplifying access to fecal occult blood test cards), or made system-level changes (for example, using systematic screening as opposed to opportunistic screening) were effective in enhancing use of CRC screening was strong. Evidence on how best to enhance discussions about CRC screening options is limited. No studies focused on reducing overuse, and very few focused on misuse. Reporting and publication bias may have affected our findings. The independent effect of individual elements of multicomponent interventions was often uncertain. Although CRC screening is underused overall, important problems of overuse and misuse also exist. System- and policy-level interventions that target vulnerable populations are needed to reduce underuse. Interventions aimed at reducing barriers by making the screening process easier are likely to be effective. Studies aimed at reducing overuse and misuse and at enhancing the quality and frequency of discussions about CRC screening options are needed. Agency for Healthcare Research and Quality.

1 October 2018 in JAMA Internal Medicine
Verified
Journal Article
Closed access
PDF file
ABAlison T. Brenner
Alison T. Brenner
TMTeri Malo
Teri Malo
MMMarjorie Margolis
Marjorie Margolis
JLJennifer Elston Lafata
Jennifer Elston Lafata
SJShynah James
Shynah James
DRDaniel S. Reuland
Daniel S. Reuland
Importance The US Preventive Services Task Force recommends that shared decision making (SDM) involving a thorough discussion of benefits and harms should occur between clinicians and patients before initiating lung cancer screening (LCS) with low-dose computed tomography. The Centers for Medicare & Medicaid Services require an SDM visit using a decision aid as a prerequisite for LCS coverage. However, little is known about how SDM about LCS occurs in practice. Objective To assess the quality of SDM about the initiation of LCS in clinical practice. Design, Setting, and Participants A qualitative content analysis was performed of transcribed conversations between primary care or pulmonary care physicians and 14 patients presumed to be eligible for LCS, recorded between April 1, 2014, and March 1, 2018, that were identified within a large database. Main Outcomes and Measures Independent observer ratings of communication behaviors of physicians using the OPTION (Observing Patient Involvement in Decision Making) scale, a validated 12-item measure of SDM (total score, 0-100 points, where 0 indicates no evidence of SDM and 100 indicates evidence of SDM at the highest skill level); time spent discussing LCS during visits; and evidence of decision aid use. Results A total of 14 conversations about initiating LCS were identified; 9 patients were women, and 5 patients were men; the mean (SD) patient age was 63.9 (5.1) years; 7 patients had Medicare, and 8 patients were current smokers. Half the conversations were conducted by primary care physicians. The mean total OPTION score for the 14 LCS conversations was 6 on a scale of 0 to 100 (range, 0-17). None of the conversations met the minimum skill criteria for 8 of the 12 SDM behaviors. Physicians universally recommended LCS. Discussion of harms (such as false positives and their sequelae or overdiagnosis) was virtually absent. The mean total visit length of a discussion was 13:07 minutes (range, 3:48-27:09 minutes). The mean time spent discussing LCS was 0:59 minute (range, 0:16-2:19 minutes), or 8% of the total visit time (range, 1%-18%). There was no evidence that decision aids or other patient education materials for LCS were used. Conclusions and Relevance In this small sample of recorded encounters about initiating LCS, the observed quality of SDM was poor and explanation of potential harms of screening was virtually nonexistent. Time spent discussing LCS was minimal, and there was no evidence that decision aids were used. Although these findings are preliminary, they raise concerns that SDM for LCS in practice may be far from what is intended by guidelines.

1 July 2017 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
DRDaniel S. Reuland
Daniel S. Reuland
ABAlison T. Brenner
Alison T. Brenner
RHRichard Hoffman
Richard Hoffman
AMAndrew McWilliams
Andrew McWilliams
RRRobert L. Rhyne
Robert L. Rhyne
MPMichael P. Pignone
Michael P. Pignone
Colorectal cancer (CRC) is the third leading cause of cancer death in men and women in the United States.1 Although non-Hispanic whites have experienced declines in CRC incidence and mortality, other racial/ethnic minority groups have not experienced similar declines.2 Colorectal cancer screening is effective at reducing CRC mortality, and expert groups, including the US Preventive Services Task Force (USPSTF) recommend CRC screening with several testing options.3-5 The US National Colorectal Cancer Roundtable, a coalition of public, private, and volunteer organizations, has set a goal of increasing US screening rates to 80% by 2018, an ambitious target that would have a substantial public health impact.6,7 Unfortunately, screening remains underused, especially among vulnerable populations, including those with Medicaid, no health insurance, low educational attainment, limited English proficiency, and members of racial/ethnic minority groups.8-14 Screening rates among Latinos, the largest racial/ethnic minority group in the United States, are substantially lower than in the general population.9,13,15,16 To increase CRC screening nationally, interventions that address multiple patient- and system-level screening barriers are needed, particularly in care settings where diverse, vulnerable populations are served.

12 January 2018 in BMC Medical Informatics and Decision Making
Verified
Journal Article
Open access
PDF file
DRDaniel S. Reuland
Daniel S. Reuland
LCLaura Cubillos
Laura Cubillos
ABAlison T. Brenner
Alison T. Brenner
RHRussell P. Harris
Russell P. Harris
BMBailey Minish
Bailey Minish
MPMichael P. Pignone
Michael P. Pignone
The United States Preventive Services Task Force (USPSTF) issued recommendations for older, heavy lifetime smokers to complete annual low-dose computed tomography (LDCT) scans of the chest as screening for lung cancer. The USPSTF recommends and the Centers for Medicare and Medicaid Services require shared decision making using a decision aid for lung cancer screening with annual LDCT. Little is known about how decision aids affect screening knowledge, preferences, and behavior. Thus, we tested a lung cancer screening decision aid video in screening-eligible primary care patients. We conducted a single-group study with surveys before and after decision aid viewing and medical record review at 3 months. Participants were active patients of a large US academic primary care practice who were current or former smokers, ages 55–80 years, and eligible for screening based on current screening guidelines. Outcomes assessed pre-post decision aid viewing were screening-related knowledge score (9 items about screening-related harms of false positives and overdiagnosis, likelihood of benefit; score range = 0–9) and preference (preferred screening vs. not). Screening behavior measures, assessed via chart review, included provider visits, screening discussion, LDCT ordering, and LDCT completion within 3 months. Among 50 participants, knowledge increased from pre- to post-decision aid viewing (mean = 2.6 vs. 5.5, difference = 2.8; 95% CI 2.1, 3.6, p < 0.001). Preferences across the overall sample remained similar such that 54% preferred screening at baseline and 50% after viewing; however, 28% of participants changed their preference (to or away from screening) from baseline to after viewing. We assessed screening behavior for 36 participants who had a primary care visit during the 3-month period following enrollment. Eighteen of 36 preferred screening after decision aid viewing. Of these 18, 10 discussed screening, 8 had a test ordered, and 6 completed LDCT. Among the 18 who preferred no screening, 7 discussed screening, 5 had a test ordered, and 4 completed LDCT. In primary care patients, a lung cancer screening decision aid improved knowledge regarding screening-related benefits and harms. Screening preferences and behavior were heterogeneous. This study is registered at www.clinicaltrials.gov . NCT03077230 (registered retrospectively,November 22, 2016).

1 September 2009 in The Annals of Family Medicine
Verified
Journal Article
Closed access
DRD. S. Reuland
D. S. Reuland
ACA. Cherrington
A. Cherrington
GWG. S. Watkins
G. S. Watkins
DBD. W. Bradford
D. W. Bradford
RBR. A. Blanco
R. A. Blanco
BGB. N. Gaynes
B. N. Gaynes
To make decisions about implementing systematic depression screening, primary care physicians who serve Spanish-speaking populations need to know whether Spanish language depression-screening instruments are accurate. We aimed to review systematically the evidence regarding diagnostic accuracy of depression-screening instruments in Spanish-speaking primary care populations. We searched PubMed, PsycINFO, CINAHL, EMBASE, and Cochrane Libraries from inception to May 28, 2008, for studies examining the diagnostic accuracy of Spanish language depression case-finding instrument(s) administered to primary-care outpatients. Two authors independently assessed studies for inclusion and quality. Twelve studies met inclusion criteria. In general primary care screening, the Spanish language version of the Center for Epidemiologic Studies-Depression scale (CES-D) had sensitivities ranging from 76% to 92% and specificities ranging from 70% to 74%. We found no US study reporting the accuracy of the Primary Care Evaluation of Mental Disorders (PRIME-MD-9) or the Patient Health Questionnaire (PHQ-9) depression module in Spanish-speakers. One fair-quality European study and 1 poor-quality study conducted in Honduras found the 9-item PRIME-MD had sensitivities ranging from 72% to 77% and specificities ranging from 86% to 100%. The 2-item PRIME-MD was 92% sensitive, but only 44% specific for depression in 1 US study. In geriatric outpatients, the 15-item Spanish language version of the Geriatric Depression Scale (GDS) had sensitivities ranging from 76% to 82%, and specificities ranging from 64% to 98%. In postpartum women, the Spanish language version of the Edinburgh Postnatal Depression Scale (EPDS) was 72% to 89% sensitive and 86% to 95% specific for major depression (2 non-US studies). The Spanish language version of the Postpartum Depression Screening Scale (PDSS) was 78% sensitive and 85% specific for combined major/minor depression (1 US study). For depression screening in Spanish-speaking outpatients, fair evidence supports the diagnostic accuracy of the CES-D and PRIME-MD-9 in general primary care, the GDS-15-Spanish for geriatric patients, and the Spanish language versions of the EPDS or PDSS for postpartum patients. The ultrashort 2-item version of PRIME-MD may lack specificity in US Spanish-speakers.

2 September 2016 in American Journal of Preventive Medicine
Verified
Journal Article
Closed access
PDF file
RVRobert J. Volk
Robert J. Volk
SLSuzanne K. Linder
Suzanne K. Linder
MLMaria A. Lopez-Olivo
Maria A. Lopez-Olivo
GKGeetanjali R. Kamath
Geetanjali R. Kamath
DRDaniel S. Reuland
Daniel S. Reuland
MPMichael P. Pignone
Michael P. Pignone